News and reporting on prostate cancer.
Protein platforms revenues grew 21 percent, while biotechnology revenues were up 18 percent, and diagnostic revenues increased 2 percent.
The firm said it saw strong reimbursement for the Oncotype DX Breast Recurrence test and increased private payor reimbursement for its Genomic Prostate test.
Exosome markets a urine-based test called ExoDx Prostate (IntelliScore) to help determine whether patients with ambiguous PSA tests needs a prostate biopsy.
In Cell this week: structural variants affecting regulatory loci in prostate cancer, immune features in the breast cancer microenvironment, and more.
Palmetto proposes to cover the assay for prostate cancer patients who are at very low and low risk of negative outcomes with active surveillance by NCCN guidelines.
The final LCD, which expands Medicare coverage of the firm's ConfirmMDx test to all providers, becomes effective on Sept. 3.
The company hopes to launch its first clinical cancer test within the next year, after spending the last several years conducting validation studies.
One study characterized an allele linked to aggressive prostate cancer, while the other explored the range of structural variations within metastatic disease.
The work is being funded with $26.5 million from the 21st Century Cures Cancer Moonshot Initiative.
Researchers characterized genetic, transcriptomic, and clinical features in advanced prostate cancers that emerged from treatment.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.